Familial pancreatic carcinoma

Familial pancreatic carcinoma (FPC), also known as familial pancreatic cancer, is a hereditary predisposition to pancreatic adenocarcinoma defined by the occurrence of pancreatic cancer in two or more first-degree relatives within a family, in the absence of another known hereditary cancer syndrome. It accounts for approximately 5–10% of all pancreatic cancer cases. The disease primarily affects the exocrine pancreas, where malignant tumors develop in the ductal epithelium, leading to progressive obstruction of the pancreatic and bile ducts. Key symptoms include abdominal or back pain, unexplained weight loss, jaundice, new-onset diabetes mellitus, nausea, loss of appetite, and steatorrhea (fatty stools). Because pancreatic cancer is often diagnosed at an advanced stage, prognosis remains poor. Several susceptibility genes have been implicated in familial pancreatic carcinoma, including BRCA2, PALB2, ATM, CDKN2A, STK11, and PRSS1, though in many families the causative gene remains unidentified. The risk of developing pancreatic cancer increases with the number of affected first-degree relatives. Individuals from FPC kindreds may also have an elevated risk of other malignancies. Surveillance programs using endoscopic ultrasound (EUS) and magnetic resonance imaging (MRI/MRCP) are recommended for high-risk individuals, typically beginning at age 50 or 10 years before the youngest age of diagnosis in the family. Treatment of pancreatic cancer in the familial setting follows standard oncologic approaches, including surgical resection (pancreaticoduodenectomy or distal pancreatectomy) when feasible, chemotherapy (such as FOLFIRINOX or gemcitabine-based regimens), and radiation therapy. Genetic counseling and germline genetic testing are strongly recommended for affected families to guide screening, risk management, and potential targeted therapies such as PARP inhibitors for BRCA2-associated tumors.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Familial pancreatic carcinoma